Categories: News

The Alliance for Artificial Intelligence in Healthcare Adds Google, Roche as Members to Advocate for Solutions to the World’s Biggest Health Challenges

BALTIMORE, May 25, 2021 /PRNewswire-PRWeb/ — The Alliance for Artificial Intelligence in Healthcare (AAIH) today announced the enrollment of multiple new members in Q1 2021, growing the organization to nearly 50 companies across the healthcare, life science, and technology industries. Joining on to support the advancement of AI in healthcare are Amicus Therapeutics, BioSig Technologies, CancerLinq, Celeris Therapeutics, Gain Therapeutics, Google, Hub Security, Lifebit, and Roche, joining founding members that include Recursion, Insilico Medicine, Valo and Janssen, the pharmaceutical companies of Johnson & Johnson.

Founded in 2018, AAIH is the leading international advocacy organization for the responsible adoption and application of AI/ML technologies across the healthcare umbrella. By bringing together stakeholders from industry, government, academia, and finance, AAIH seeks to foster changes that result in the best outcomes for patients.

“Over the last few years, we have seen almost limitless opportunities for AI to disrupt all points of the healthcare spectrum — from medical records to drug discovery. But we need to focus on where we can have the most tangible impact now and what to work towards in the long term,” said Brandon Allgood, Ph.D., Chief AI Officer, Valo Health, and chairperson of AAIH. “We are excited to welcome such well-recognized thought leaders and look forward to hearing their perspectives on how we can make a more substantial impact in the use of AI technologies.”

In 2021, AAIH established four primary focus areas as the most immediate priorities: (1) Data Access, Quality, and Usability; (2) Fairness and Equity in the Application of AI; (3) Establishing an Effective Regulatory Framework; (4) Data and Technology Standards for AI/ML. Working groups have been stood up and progress reports are planned throughout the remainder of the year. Those interested in participating should direct membership inquiries to info@theaaih.org.

In Summer 2021, AAIH will host its second annual “IMAGINE: AI + Healthcare Leadership Summit,” which convenes global thought leaders to tackle key issues and elucidate promising opportunities towards the shared mission. For more information and to register for future updates on the summit, please visit our website.

ABOUT AAIH

The Alliance for Artificial Intelligence in Healthcare (AAIH) is an international advocacy organization dedicated to the responsible adoption and application of AI/ML in healthcare. Our members represent all healthcare sectors, including drug R&D, digital health, medical devices, healthcare delivery, data science & technology providers with a shared goal of improving the state of healthcare globally through AI-enabled solutions. For more information, please visit http://www.theaaih.org

Media Contact

Andrea Vuturo, Vuturo Group, +1 4156898414, info@theaaih.org

Twitter

 

SOURCE Alliance for Artificial Intelligence in Healthcare

Staff

Recent Posts

Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE:…

35 mins ago

Akanda Corporation Announces Completion of F-3 Shelf Registration Statement

London, United Kingdom--(Newsfile Corp. - June 14, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or…

35 mins ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today…

2 hours ago

Justera Health Signs LOI to Acquire Popular Cannabis Brand Port North

Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink:…

2 hours ago

OneMedNet Partners with Leading Clinical Trial Design and Software Company in Significant Data License Agreement

Partner’s software products and services are utilized by hundreds of life science organizations, including the…

2 hours ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production…

2 hours ago